Brief: ABVC Biopharma Says Vitargus Phase II Study On Hold Due To Serious Adverse Events
09/06/2023 22:52
June 9 (Reuters) - ABVC Biopharma Inc ABVC.O :
* ABVC BIOPHARMA INC - VITARGUS PHASE II STUDY WAS PUT ON
HOLD DUE
TO SERIOUS ADVERSE EVENTS (SAES) OBSERVED IN PATIENTS
Further company coverage: ABVC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ABVC Biopharma
See all newsBrief: ABVC Biopharma Says Biokey Share Distribution Rescheduled For August 21
NASDAQ RESUMED AT 09:05 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 04:43 PM
Brief: ABVC Biopharma - Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon